Staking out novelty on the genomic frontier.
Recent advances in genomics include global assessment and classification of genome content, high-throughput biological pathway construction, systematic identification of previously unpredicted genes and the in vitro creation of novel motifs with biological function not found in nature (extra-genomic gene discovery). The ability to make global surveys of transcriptomes has given rise to fields such as pharmacogenomics and toxicogenomics. These applications of genomics technologies, with conventional drug assessment methodologies, will lead to more tolerable drugs and a better understanding of clinical populations. Integration of pathway mapping, using proteomics married to expression, will also significantly affect how new therapeutics are discovered as cross-biological cross-pathway interactions lead to novel drug targets and better predictions of drug tolerance.
CuraGen Corporation, Department of Collaborative Research, 555 Long Wharf Drive, New Haven, Connecticut 06511, USA.
Kerry E
KE
Quinn-Senger
Ravi
R
Ramachandran
Joseph A
JA
Rininger
Karen M
KM
Kelly
David A
DA
Lewin
D017398:Alternative Splicing; D000818:Animals; D001483:Base Sequence; D030561:Databases, Nucleic Acid; D020869:Gene Expression Profiling; D023281:Genomics / Q000379:methods / Q000639:trends*; D006801:Humans; D020641:Polymorphism, Single Nucleotide; D017385:Sequence Homology